Wells Fargo adjusted its outlook on Merit Medical Systems , Inc. (NASDAQ:MMSI) by increasing the price target to $103 from the previous $85, while maintaining an Equal Weight rating on the stock. The revision follows the announcement of clinical study results that demonstrated the effectiveness of the company's Wrapsody device.
Merit Medical's Wrapsody device was evaluated in the WAVE study, which included 122 patients with arteriovenous (AV) fistula. The study's findings revealed a target lesion primary patency (TLPP) rate of 89.8%, a significant improvement compared to the 62.8% rate observed in the control group of 123 patients.
The Wrapsody device's performance was notably superior to that of competing devices, which have typically shown a TLPP rate of less than 80% at the six-month mark.
This outcome highlights the potential for Wrapsody to become a leading option in the treatment of AV fistula patients.
In addition to the TLPP rate, Wrapsody also demonstrated a strong access circuit primary patency (ACPP) rate of 72.6% at six months. This rate is substantially higher than the less than 50% ACPP rate reported for most competing devices at the same interval.
The positive results from the WAVE study suggest that Merit Medical's Wrapsody device could have a competitive advantage in the market, which is reflected in the updated price target set by Wells Fargo.
The company's shares may respond to these developments as investors consider the implications of the clinical study outcomes.
In other recent news, Merit Medical Systems has seen a flurry of positive developments. The company's share target was raised to $103 by BofA Securities following the presentation of six-month pivotal data from its WRAPSODY device. The device, designed for maintaining vascular access in hemodialysis patients, demonstrated a significant target lesion primary patency rate of 90%, surpassing the outcomes from primary competitors.
Piper Sandler also increased the price target on Merit Medical's stock to $110, in anticipation of the WAVE trial data for the WRAPSODY product. Moreover, BofA Securities raised its price target for the company's shares to $92 following strong Q2 earnings.
In financial highlights, the second quarter of 2024 saw Merit Medical's total revenue reach $338 million, marking a 5.6% increase year-over-year. This was driven by organic growth and acquired products, including the acquisition of EndoGastric Solutions for $105 million. The company's updated financial guidance for 2024 projects a net revenue increase of 6-7% and non-GAAP diluted EPS growth of 15-17%.
InvestingPro Insights
Merit Medical Systems, Inc. (NASDAQ:MMSI) has recently caught the attention of investors and analysts alike, following the promising clinical study results of its Wrapsody device. The InvestingPro data shows a robust revenue growth of 8.6% over the last twelve months as of Q2 2024, indicating a solid financial performance. The company's gross profit margin stands at an impressive 46.54%, showcasing the efficiency of its operations. Despite trading at a high earnings multiple with a P/E ratio of 47.49, Merit Medical's stock has experienced a substantial price uptick, trading near its 52-week high at 98.08% of that value.
From the InvestingPro Tips, it's notable that Merit Medical is expected to grow its net income this year, which is a positive sign for potential investors. The company also operates with a moderate level of debt, suggesting a balanced approach to leveraging and financial stability. For those looking to delve deeper into Merit Medical's financial health and future prospects, there are additional 15 InvestingPro Tips available, which could provide investors with a comprehensive analysis of the company's potential.
With an adjusted market cap of $5.6 billion, Merit Medical's financial strength is evident. The company's stock has also delivered a strong return over the last three months, with a 17.56% price total return, further underscoring the market's positive reception to its recent developments. Investors interested in the healthcare sector may find Merit Medical's financial metrics and the expert analysis from InvestingPro to be valuable resources when evaluating the company's stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.